Skip to main content
Clinical Trials/NCT01853527
NCT01853527
Completed
Not Applicable

Myocardial Ischemia in Non-obstructive Coronary Artery Disease

University of Bergen1 site in 1 country132 target enrollmentStarted: April 2013Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
132
Locations
1
Primary Endpoint
Presence of myocardial ischemia by contrast stress echocardiography

Overview

Brief Summary

The aim of the study is to assess presence of myocardial ischemia by contrast stress echocardiography in patients with symptomatic non-obstructive coronary artery disease (CAD) by CT-coronary angiography, and the clinical, vascular, biochemical and genetic markers of myocardial ischemia in such patients.

Detailed Description

Non-obstructive coronary artery disease (CAD) is particularly common in women and associated with reduced quality of life and increased cardiovascular morbidity and mortality. The project will recruit patients with angina pectoris and non-obstructive CAD by CT- coronary angiography for further imaging with contrast stress echocardiography for diagnosis of myocardial ischemia. Better characterization of patients with symptomatic non-obstructive CAD due to myocardial ischemia will be done by vascular assessment by tonometry, biochemical and genetic markers as well as quality of life questionnaire. This interdisciplinary project is expected to add new knowledge to the impact of multimodality cardiac imaging in improving diagnosis in patients with symptomatic non-obstructive CAD.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
30 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age \>30 years
  • Chest pain and or functional dyspnoea with a duration \> 6 months
  • Non-obstructive coronary artery disease detected by CT coronary angiography

Exclusion Criteria

  • Significant coronary artery stenosis or normal coronary arteries by CT coronary angiography
  • Unstable coronary artery disease
  • Significant valvular heart disease
  • Mechanical valve prosthesis
  • Significant arrhythmia
  • Severly reduced pulmonary function (GOLD 3-4)
  • Known allergy to ultrasound contrast agents
  • Pregnancy
  • Inability to sign informed consent to participate
  • Other severe disease

Outcomes

Primary Outcomes

Presence of myocardial ischemia by contrast stress echocardiography

Time Frame: 15 minutes, during contrast stress echocardopgraphy

Presence of delayed myocardial contrast enhancement during stress echocardiography

Secondary Outcomes

  • Extent of myocardial ischemia by contrast stress echocardiography(15 minutes, during contrast stress echocardiography)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mai Tone Lønnebakken

MD, phd

University of Bergen

Study Sites (1)

Loading locations...

Similar Trials